Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Isis Pharmaceuticals

Related ISIS
ISIS-STAT3 Rx And ISIS-AR Rx Data Presented By AstraZeneca At European Cancer Symposium
Isis Pharmaceuticals Prices Offering of $425M Of 1.00% Convertible Senior Notes
Making Money With Charles Payne: 10/08/14 (Fox Business)

In a report published Monday, BMO Capital Markets reiterated its Outperform rating on Isis Pharmaceuticals (NASDAQ: ISIS) and raised its price target from $12.00 to $17.00.

BMO Capital Markets noted, “We are reiterating our Outperform rating on shares of ISIS and increasing our price target to $17 following our meeting with management. With the near-term focus on the KYNAMRO PDUFA, we are increasingly confident in approval and believe that upside potential extends beyond the initial commercial opportunity and to validation of an emerging late-stage pipeline. Relative to the value of KYNAMRO in HoFH, estimated at an NPV of $3/share, we believe that pipeline value is considerably greater, with an estimated NPV of $14/share, primarily driven by only 1 of 25 programs in the ASO for ApoCIII for triglycerides.”

Isis Pharmaceuticals closed on Friday at $13.28.

Latest Ratings for ISIS

DateFirmActionFromTo
Sep 2014Leerink SwannAssumesMarket Perform
Aug 2014BMO CapitalMaintainsOutperform
Aug 2014Laidlow & Co.Initiates Coverage onBuy

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters